54th directing council; 67th session of the regional Committee of WHO for the Americas
CD54/11, Rev. 1, 2 October 2015, Original: Spanish
Copenhagen, Denmark, 24–25 August 2017
Tuberculosis MDR-TB & XDR-TB The 2008 Report
Emerging Infectious Diseases; Vol. 21, No. 11, November 2015
Updated to Reflect the 2009 Medical Eligibility Criteria of the World Health Organization
Data from l'Enquête Démographique et de Santé (EDS-RDC) en République Démocratique du Congo, 2013-14
For 50 SAM children with medical complications and for a paediatric ward of 10-15 beds for 3 months
The PED/SAM kit is especially designed to provide medicines, renewables and equipment suitable for children and to treat the common childhood illness including severe acute malnutrition with medica
...
l complications.
This kit does NOT contain any food supplements, TB, HIV medicines or vaccines.
more
. MSF Essential Drugs Guidelines دليل عملي موجه للأطباء والصيادلة والممرضين والمساعدين الطبيين
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
Policy brief based on the 2007 Rwanda Service Provision Assessment (RSPA) survey. The 2007 RSPA survey describes how the formal health sector in Rwanda provides services for family planning, maternal health, child health, malaria, HIV/AIDS, and other communicable diseases.
The WHO South-East Asia (SEA) Region bears a high burden of tuberculosis (TB) and MDR-TB. In 2015, the Region accounted for nearly 200 000 or 35% of the global estimated new RR/MDR-TB cases eligible for treatment. Extensively drug-resistant TB (XDRTB) has also been reported from s
...
ix countries of the SEA Region. MDR-TB could potentially replace drug-susceptible TB, and constitutes a threat to global public health security. The South- East Asia Regional Response Framework for DR-TB 2017–2021 complements the Ending TB in the South-East Asia Region: Regional Strategic Plan 2016–2020” and outlines key strategies for reducing morbidity, mortality and transmission of DR-TB.
more